Last reviewed · How we verify
DAS181 OL
DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses.
DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses. Used for Respiratory viral infections (influenza, COVID-19, other respiratory viruses).
At a glance
| Generic name | DAS181 OL |
|---|---|
| Sponsor | Ansun Biopharma, Inc. |
| Drug class | Recombinant fusion protein / Antiviral |
| Target | ACE2 receptor domain (viral spike protein binding) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
DAS181 consists of the extracellular domain of human ACE2 fused to the Fc region of human IgG1, enabling it to bind to viral spike proteins and prevent viral attachment to host cells. This mechanism allows it to act as a decoy receptor, sequestering virus particles and reducing viral infectivity. The drug is designed to provide broad antiviral activity against multiple respiratory viruses including influenza and coronaviruses.
Approved indications
- Respiratory viral infections (influenza, COVID-19, other respiratory viruses)
Common side effects
- Injection site reactions
- Infusion-related reactions
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |